drugset / Trial / NCT05845996
Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Primary Objective is the tolerability and safety of ascending single and repeated intravenous infusion (IV) and/or subcutaneous (SC) administration of SAR441344
Timeline
- Start
- 2018-11-08
- Primary completion
- 2020-04-10
- Completion
- 2020-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Frexalimab | Monoclonal antibody | — | Intravenous |
| Background | keyhole limpet hemocyanin | Vaccine | — | Subcutaneous |
Indications
No indication recorded.